JPWO2022133592A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022133592A5 JPWO2022133592A5 JP2023537488A JP2023537488A JPWO2022133592A5 JP WO2022133592 A5 JPWO2022133592 A5 JP WO2022133592A5 JP 2023537488 A JP2023537488 A JP 2023537488A JP 2023537488 A JP2023537488 A JP 2023537488A JP WO2022133592 A5 JPWO2022133592 A5 JP WO2022133592A5
- Authority
- JP
- Japan
- Prior art keywords
- cysteine residue
- trac
- tcr
- disulfide bond
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 204
- 235000001014 amino acid Nutrition 0.000 claims description 163
- 238000006467 substitution reaction Methods 0.000 claims description 84
- 150000001413 amino acids Chemical class 0.000 claims description 79
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 78
- 229920001184 polypeptide Polymers 0.000 claims description 78
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 78
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 78
- 102000037865 fusion proteins Human genes 0.000 claims description 33
- 108020001507 fusion proteins Proteins 0.000 claims description 33
- 230000035772 mutation Effects 0.000 claims description 32
- 230000000087 stabilizing effect Effects 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128601P | 2020-12-21 | 2020-12-21 | |
| US63/128,601 | 2020-12-21 | ||
| PCT/CA2021/051855 WO2022133592A1 (en) | 2020-12-21 | 2021-12-21 | Stabilized tcr constructs and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023554119A JP2023554119A (ja) | 2023-12-26 |
| JP2023554119A5 JP2023554119A5 (https=) | 2025-01-06 |
| JPWO2022133592A5 true JPWO2022133592A5 (https=) | 2025-01-06 |
Family
ID=82157307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537488A Pending JP2023554119A (ja) | 2020-12-21 | 2021-12-21 | 安定化されたｔｃｒコンストラクト及び使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240409604A9 (https=) |
| EP (1) | EP4263593A4 (https=) |
| JP (1) | JP2023554119A (https=) |
| KR (1) | KR20230123474A (https=) |
| CN (1) | CN116648256A (https=) |
| AU (1) | AU2021408160A1 (https=) |
| CA (1) | CA3167637A1 (https=) |
| WO (1) | WO2022133592A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| WO2025087436A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京可瑞生物科技有限公司 | 基于t细胞受体的多特异性多肽分子及其组合物和用途 |
| WO2025140554A1 (en) * | 2023-12-29 | 2025-07-03 | Shanghai Epimab Biotherapeutics Co., Ltd. | Fusion proteins and uses thereof |
| CN118108833B (zh) * | 2024-03-12 | 2025-05-02 | 缇纱(合肥)生物技术有限公司 | 引入外源二硫键的tcr恒定区及其产品和应用 |
| WO2025214470A1 (zh) * | 2024-04-12 | 2025-10-16 | 江苏恒瑞医药股份有限公司 | 包含t细胞受体恒定区的蛋白质及其医药用途 |
| WO2025224084A1 (en) | 2024-04-22 | 2025-10-30 | Engimmune Therapeutics Ag | Proteins comprising t cell receptor constant domains |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110139873A (zh) * | 2016-10-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| CN117843810A (zh) * | 2017-09-22 | 2024-04-09 | 上海药明生物技术有限公司 | 新型双特异性多肽复合物 |
| AU2018337142B2 (en) * | 2017-09-22 | 2025-07-03 | Wuxi Biologics Ireland Limited. | Novel bispecific CD3/CD19 polypeptide complexes |
| BR112020006643A2 (pt) * | 2017-10-03 | 2020-09-24 | Juno Therapeutics Inc | moléculas de ligação específica ao hpv |
| KR20210020873A (ko) * | 2018-04-05 | 2021-02-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법 |
| AU2019249209A1 (en) * | 2018-04-05 | 2020-10-15 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
-
2021
- 2021-12-21 AU AU2021408160A patent/AU2021408160A1/en not_active Abandoned
- 2021-12-21 JP JP2023537488A patent/JP2023554119A/ja active Pending
- 2021-12-21 CN CN202180086149.4A patent/CN116648256A/zh active Pending
- 2021-12-21 EP EP21908193.2A patent/EP4263593A4/en active Pending
- 2021-12-21 CA CA3167637A patent/CA3167637A1/en active Pending
- 2021-12-21 US US18/258,057 patent/US20240409604A9/en active Pending
- 2021-12-21 WO PCT/CA2021/051855 patent/WO2022133592A1/en not_active Ceased
- 2021-12-21 KR KR1020237020556A patent/KR20230123474A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015357053B2 (en) | Domain-exchanged antibody | |
| KR102833184B1 (ko) | 향상된 이중 특이성 폴리펩티드 분자 | |
| JP7847584B2 (ja) | 免疫細胞機能をモジュレートするためのｃｄ８抗原結合分子を有する融合物 | |
| US5932448A (en) | Bispecific antibody heterodimers | |
| EP2794658B1 (en) | Bispecific antibody molecule | |
| AU2022350407B2 (en) | Interleukin-2 mutant and fusion protein thereof | |
| CN110382537B (zh) | 抗体结构域的优选配对 | |
| CN107001468A (zh) | Cd3结合结构域 | |
| KR20210010896A (ko) | 이기능성 결합 폴리펩타이드 | |
| JP5750373B2 (ja) | 慢性炎症性応答の調節および自己免疫疾患の処置のためのｉｌ−４由来ペプチド | |
| JPH05500068A (ja) | 可溶性一本鎖ｔ細胞レセプター | |
| KR950701386A (ko) | 레스피라토리 신시티알 바이러스 감염증의 치료 및 예방용 항체(Antibodies For Treatment And Prevention Of Resipiratory Syncytial Virus infection) | |
| WO2022125694A1 (en) | Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function | |
| US20250243275A1 (en) | Multi-domain binding molecules | |
| JPWO2022133592A5 (https=) | ||
| JPWO2021185361A5 (https=) | ||
| KR970070198A (ko) | 항-파스 재조합 항체 및 이에 대한 디엔아이 | |
| WO2023222035A1 (zh) | 抗tigit抗体与il2的融合蛋白或其变体及其应用 | |
| CN120112558A (zh) | 治疗慢性病毒感染的含cd8抗原结合分子的融合物 | |
| KR20240024241A (ko) | 인터루킨 15 변이체 | |
| JP2024517658A (ja) | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節ポリペプチド及びその使用方法 | |
| Calaman et al. | Characterization of monoclonal antibodies specific for the Vβ3 family of the human T cell receptor generated using soluble TCR β-chain | |
| JPH05304991A (ja) | Ｉｌ−２受容体重鎖に結合するポリペプチド | |
| JPWO2021255127A5 (https=) | ||
| RU2025135483A (ru) | Рекомбинантный слитый белок для лечения легочной гипертензии |